Download PGS
(Variants and weights)

Polygenic Score (PGS) ID: PGS000058

Predicted Trait

Reported Trait: Coronary artery disease
Mapped Trait(s) (Experimental Factor Ontology (EFO) IDs): coronary artery disease

Score Details

Name: CAD_GRS_204

Original Genome Build: hg19
Number of Variants: 204

PGS Development Method: Genome-wide significant SNPs
PGS Development Details/Relevant Parameters: Variants with a genome-wide significant associations with CAD in GWAS and exome-wide association studies published as of December 2017

Citation: Morieri ML et al. Diabetes Care (2018) | PGS Catalog Publication ID: PGP000043

Contributing Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry
GWAS Catalog: GCST005194
PubMed: 29212778
296,525 individuals NR
GWAS Catalog: GCST003116
PubMed: 26343387
11,323 individuals East Asian
GWAS Catalog: GCST003116
PubMed: 26343387
25,557 individuals South Asian
GWAS Catalog: GCST003116
PubMed: 26343387
2,268 individuals Greater Middle Eastern (Middle Eastern, North African or Persian)
GWAS Catalog: GCST003116
PubMed: 26343387
4,095 individuals Hispanic or Latin American
GWAS Catalog: GCST003116
PubMed: 26343387
141,217 individuals European
GWAS Catalog: GCST003116
PubMed: 26343387
3,139 individuals African American or Afro-Caribbean
GWAS Catalog: GCST004787
PubMed: 28714975
63,731 individuals European, NR
GWAS Catalog: GCST007990
PubMed: 28714974
120,286 individuals European
PubMed: 23202125.0 194,427 individuals
[ 63,746 cases, 130,681 controls]
Other
PubMed: 28530674.0 250,736 individuals
[ 88,192 cases, 162,544 controls]
Other
PubMed: 28584231.0 87,433 individuals
[ 10,898 cases, 76,535 controls]
50.81 %% Male samples
European
GWAS Catalog: GCST000999
PubMed: 21378988
14,790 individuals South Asian
(India, Pakistan)
GWAS Catalog: GCST000999
PubMed: 21378988
15,682 individuals European
PubMed: 26934567.0 120,575 individuals
[ 42,335 cases, 78,240 controls]
European
PubMed: 28209224.0 120,575 individuals
[ 42,335 cases, 78,240 controls]
European

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.
PGS Performance Metric (PPM) ID PGS Catalog Sample Set (PSS) ID Performance Source Trait PGS Effect Sizes
(per SD change)
PGS Classification Metrics Other Metrics Covariates Included in PGS Model PGS Performance: Other Relevant Information
PPM000147 PSS000092 Morieri ML et al. (2018) Reported Trait: Major coronary events (MCE) events among Type 2 Diabetes patients HR: 1.27 [1.18 - 1.37] age, sex, ACCORD study covariates (randomized treament assignement, clinical network, genotyping platform, PCs of genetic ancestry)
PPM000148 PSS000093 Morieri ML et al. (2018) Reported Trait: Major coronary events (MCE) events among Type 2 Diabetes patients HR: 1.35 [1.16 - 1.58] age, sex, ORIGIN study covariates (randomized treament assignement, PCs of genetic ancestry)

Evaluated Samples

PGS Catalog Sample Set (PSS) ID Detailed Phenotype Description (e.g. ICD/SNOMED codes used to identify cases) Sample Numbers Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000092 Incident Major coronary events (MCE) are defined as: fatal or nonfatal coronary artery disease (CAD) events, nonfatal myocardial infarction, or unstable angina 5,360 individuals
[ 675 cases, 4,685 controls]
64.80 %% Male samples
European Self reported white ACCORD Type 2 Diabetes patients
PSS000093 Incident Major coronary events (MCE) are defined as: fatal or nonfatal coronary artery disease (CAD) events, nonfatal myocardial infarction, or unstable angina 1,931 individuals
[ 163 cases, 1,768 controls]
European Self reported white ORIGIN Participants are from the Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial and were enrolled based on having some combination of impaired fasting glucose, impaired glucose tolerance or type 2 diabetes, and high cardiovascular risk